Not for the 'Faint of Heart' | GenomeWeb

Diagnostics are a tough business, writes life sciences venture capitalist Bruce Booth.

And he should know — he's currently in the process of unwinding cancer diagnostics company On-Q-Ity, an investment by his firm, Atlas Ventures, that didn't quite work out.

The reading public is the beneficiary of Booth's loss, though, as he performs a post-mortem of sorts, looking at what went wrong.

Among the lessons learned:

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.